Impact of time-of-day administration of immunotherapy on survival in metastatic renal cell carcinoma: the MOUSEION-09 meta-analysis.
Saved in:
| Title: | Impact of time-of-day administration of immunotherapy on survival in metastatic renal cell carcinoma: the MOUSEION-09 meta-analysis. |
|---|---|
| Authors: | Rizzo A; S.S.D. C.O.r.O. Bed Management Presa in Carico, TDM, IRCCS Istituto Tumori 'Giovanni Paolo II', Viale Orazio Flacco 65, Bari, 70124, Italy. rizzo.alessandro179@gmail.com., Monteiro FSM; Latin American Cooperative Oncology Group - LACOG, Porto Alegre, RS, Brazil.; Oncology and Hematology Department, Hospital Sírio-Libanês, Brasilia, DF, Brazil., Mollica V; Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy., Soares A; Latin American Cooperative Oncology Group - LACOG, Porto Alegre, RS, Brazil.; Hospital Israelita Albert Einstein, São Paulo, SP, Brazil., Brunetti O; S.S.D. C.O.r.O. Bed Management Presa in Carico, TDM, IRCCS Istituto Tumori 'Giovanni Paolo II', Viale Orazio Flacco 65, Bari, 70124, Italy., Ricci AD; Medical Oncology Unit, National Institute of Gastroenterology, IRCCS 'S. de Bellis' Research Hospital, Castellana Grotte, 70013, Italy., Massari F; Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.; Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy., Santoni M; Oncology Unit, Macerata Hospital, Macerata, Italy. |
| Source: | Clinical & experimental metastasis [Clin Exp Metastasis] 2024 Dec 16; Vol. 42 (1), pp. 3. Date of Electronic Publication: 2024 Dec 16. |
| Publication Type: | Journal Article; Meta-Analysis; Systematic Review |
| Journal Info: | Publisher: Kluwer Academic Publishers Country of Publication: Netherlands NLM ID: 8409970 Publication Model: Electronic Cited Medium: Internet ISSN: 1573-7276 (Electronic) Linking ISSN: 02620898 NLM ISO Abbreviation: Clin Exp Metastasis Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
